Medication info
Rovitane Tablet 5 mg (Rosuvastatin Calcium)

Rovitane Tablet 5 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Sam-il Pharmaceutical Co., Ltd.
Appearance
Yellow, round film-coated tablets
Packaging
14 tablets/blister X 2
Approval status
Active

MFDS item code 201001007 · Approved 2010.01.28 · Insurance code 643902800

Summary

Main use
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased up to a maximum of 20 milligrams once daily. 3. Older adults : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. This medicine should not be administered to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. This medicine should not be administered to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this medicine is contraindicated in some of these patients.
Child dose
Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Sam-il Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • excess LDL cholesterol
  • excess total cholesterol
  • high Apo-B protein levels
  • primary dysbetalipoproteinemia
  • cardiovascular disease risk factors
  • hypertension
View approved original text

This medication is used as an adjunct when dietary management and exercise are not enough to control primary hypercholesterolemia and mixed dyslipidemia patients. It is also used in conjunction with dietary restrictions or LDL apheresis in patients with homozygous familial hypercholesterolemia. This medication helps lower total cholesterol and LDL cholesterol levels in hypercholesterolemia patients and delays the progression of atherosclerosis. It is also administered as an adjunct to diet for pediatric patients aged 10 to 17 with heterozygous familial hypercholesterolemia. This medication also acts as an adjunct to diet in patients with primary dysbetalipoproteinemia, reducing cardiovascular disease risk, as well as the risk of stroke, myocardial infarction, and recurrence after arterial revascularization. This medication improves blood cholesterol and cardiovascular disease risk factors, thereby enhancing patient health.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased up to a maximum of 20 milligrams once daily. 3. Older adults : No dose adjustment is necessary. 4. Patients with renal impairment : No dose adjustment is necessary in patients with mild or moderate renal impairment. This medicine should not be administered to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment : No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. This medicine should not be administered to patients with active liver disease. 6. Race : Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 7. Patients predisposed to myopathy : The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this medicine is contraindicated in some of these patients.

Child dose

Ages 10 to 17 years: The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, patients with an allergy to the ingredients of this medication, severely impaired liver function, muscle disorders, severe kidney dysfunction, and women who are pregnant or breastfeeding should not take this medication. Additionally, this medication should be used cautiously in patients at high risk for muscle disorders or those taking certain medications. Because this medication can affect liver function, patients with a history of liver disease or excessive alcohol consumption should undergo liver function tests before taking it and periodically during treatment. If symptoms such as muscle pain or weakness occur, medical personnel should be informed immediately, and blood tests should be conducted to check for muscle damage. If muscle damage is severe, medication may need to be discontinued. This medication may elevate blood sugar levels in some people; therefore, patients at risk for diabetes should monitor their blood sugar levels periodically. Additionally, the response to this medication and its side effects can vary based on genetic factors, so dosage adjustments may be necessary in consultation with medical personnel. Serious skin reactions may occur during treatment; if skin rashes, swelling, or severe itching develop, medication should be discontinued immediately, and medical personnel should be consulted. This medication may interact with other drugs; if other medications are being taken, it is essential to inform medical personnel. Caution is needed when used with medications that affect liver function or increase the risk of muscle damage. Women of childbearing potential should use appropriate contraception to avoid becoming pregnant while taking this medication, and should discontinue use immediately if pregnancy occurs. Nursing women should also avoid taking this medication. In case of overdose, since there is no specific antidote, it is important to receive symptomatic treatment and conduct liver function and muscle-related tests. This medication is known not to significantly affect the ability to drive or operate machinery, but caution is advised due to potential dizziness. Finally, this medication may show higher concentrations in Asian individuals, requiring dosage adjustments.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, hives, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), fixed drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it should be kept at room temperature between 1 and 30 degrees Celsius. Storing it this way ensures the effectiveness of the medication is maintained safely.

Appearance and packaging

Appearance

Yellow, round film-coated tablets

Package unit

14 tablets/blister X 2

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.